{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:47:52Z","timestamp":1782190072337,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","painmanagementnursing.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pain Management Nursing"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pmn.2026.05.028","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:09:09Z","timestamp":1782187749000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SCD Medications Use and Pain Events Among SCD Patients in a Nigerian Hospital"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-8967","authenticated-orcid":false,"given":"Ogochukwu","family":"Izuegbuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Kolawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawale","family":"Olakulehin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4314\/ahs.v17i1.31","article-title":"Hydroxyurea therapy in adult Nigerian sickle cell disease: A monocentric survey on pattern of use, clinical effects and patient's compliance","volume":"17","author":"Adewoyin","year":"2017","journal-title":"African Health Sciences"},{"key":"10.1016\/j.pmn.2026.05.028_bib0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.11604\/pamj.2019.34.88.17257","article-title":"Clinical and socio-demographic determinants of pentazocine misuse among patients with sickle cell disease, Benin City, Nigeria: A case-control study","volume":"34","author":"Adewoyin","year":"2019","journal-title":"The Pan African Medical Journal"},{"issue":"3","key":"10.1016\/j.pmn.2026.05.028_bib0004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.18295\/squmj.3.2024.019","article-title":"Health-related quality of life of Omani adult patients with sickle cell disease at the Sultan Qaboos University Hospital","volume":"24","author":"Al-Hinai","year":"2024","journal-title":"*Sultan Qaboos University Medical Journal"},{"key":"10.1016\/j.pmn.2026.05.028_bib0005","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2147\/PPA.S434750","article-title":"Impact of sickle cell disease on academic performance: A cross sectional study","volume":"17","author":"Alsalman","year":"2023","journal-title":"Patient Preference and Adherence"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0006","article-title":"Health-related quality of life among patients with sickle cell disease in an adult hematology clinic in a tertiary hospital in Lagos","volume":"14","author":"Amaeshi","year":"2022","journal-title":"Nigeria. Cureus"},{"key":"10.1016\/j.pmn.2026.05.028_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/JBM.S380901","article-title":"Outcomes of hydroxyurea accessed via various means and barriers affecting its usage among children with sickle cell anaemia in north-western Tanzania","volume":"14","author":"Ambrose","year":"2023","journal-title":"Journal of Blood Medicine"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0008","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00277-024-06180-2","article-title":"Use of hydroxyurea in French-speaking Sub-Saharan Africa","volume":"104","author":"Arlet","year":"2025","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.pmn.2026.05.028_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100901","article-title":"Impact of hospitalized vaso-occlusive crises in the previous calendar year on mortality and complications in adults with sickle cell disease: A French population-based study","volume":"40","author":"Arlet","year":"2024","journal-title":"The Lancet Regional Health \u2013 Europe"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75078-w","article-title":"Computational screening of phytochemicals present in some Nigerian medicinal plants against sickle cell disease","volume":"14","author":"Asibor","year":"2024","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0011","first-page":"83","article-title":"Awareness and pattern of pentazocine use in patients with sickle cell disease in two sickle cell clinics in Lagos state","volume":"55","author":"Ayeni","year":"2021","journal-title":"Nigeria. The Nigerian Journal of Pharmacy"},{"issue":"18","key":"10.1016\/j.pmn.2026.05.028_bib0012","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: A critical reappraisal","volume":"120","author":"Ballas","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pmn.2026.05.028_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.gpeds.2024.100193","article-title":"Socio-economic burden of sickle cell disease on families attending sickle cell clinic in Kano state, northwestern Nigeria","volume":"9","author":"Beli","year":"2024","journal-title":"Global Pediatrics"},{"issue":"1\u20132","key":"10.1016\/j.pmn.2026.05.028_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","article-title":"Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)","volume":"114","author":"Bouhassira","year":"2005","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.pmn.2026.05.028_bib0015","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Advances"},{"issue":"20","key":"10.1016\/j.pmn.2026.05.028_bib0016","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"Supplement 1","key":"10.1016\/j.pmn.2026.05.028_bib0017","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-200182","article-title":"Bruton tyrosine kinase inhibitor rilzabrutinib reduces vaso-occlusion and markers of inflammation and adhesion in transgenic mice with sickle cell disease","volume":"144","author":"Daak","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pmn.2026.05.028_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"European Journal of Haematology"},{"issue":"11","key":"10.1016\/j.pmn.2026.05.028_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079923","article-title":"Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study","volume":"8","author":"Darbari","year":"2013","journal-title":"PLOS ONE"},{"issue":"Supplement 1","key":"10.1016\/j.pmn.2026.05.028_bib0020","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1182\/blood-2024-212305","article-title":"Jobelyn, a Sorghum bicolor extract-based oral supplement reduces oxidative stress in school aged children with sickle cell disease","volume":"144","author":"Diaku-Akinwumi","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pmn.2026.05.028_bib0021","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s11136-025-03963-6","article-title":"Health-related quality of life and economic impacts in adults with sickle cell disease with recurrent vaso-occlusive crises: Findings from a prospective longitudinal real-world survey","volume":"34","author":"Drahos","year":"2025","journal-title":"Quality of Life Research"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0022","doi-asserted-by":"crossref","first-page":"314","DOI":"10.30574\/gscbps.2023.25.2.0493","article-title":"The hidden toll: Assessing the economic burden of pentazocine dependence on sickle cell disease patients in Nsukka local government Area, Enugu State, Nigeria","volume":"25","author":"Eze","year":"2023","journal-title":"GSC Biological and Pharmaceutical Sciences"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0023","doi-asserted-by":"crossref","first-page":"62","DOI":"10.38029\/babcockuniv.med.j..v6i2.182","article-title":"Anti-craving property of chlorpromazine in pentazocine addiction among sickle cell disease patients: A case series","volume":"6","author":"Falade","year":"2023","journal-title":"Babcock University Medical Journal"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0885-3924(01)00407-9","article-title":"Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool","volume":"23","author":"Franck","year":"2002","journal-title":"Journal of Pain and Symptom Management"},{"issue":"11","key":"10.1016\/j.pmn.2026.05.028_bib0025","article-title":"Black Americans with Sickle Cell Disease (SCD) demonstrate accelerated epigenetic pace of aging compared to Black Americans without SCD","volume":"79","author":"Garrett","year":"2024","journal-title":"The Journals of Gerontology: Series A"},{"issue":"4","key":"10.1016\/j.pmn.2026.05.028_bib0026","article-title":"Opioid prescribing for acute pain management in children and adolescents in outpatient settings: Clinical practice guideline","volume":"154","author":"Hadland","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.pmn.2026.05.028_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.786065","article-title":"Academic performance of children with sickle cell disease in the United States: A meta-analysis","volume":"12","author":"Heitzer","year":"2021","journal-title":"Frontiers in Neurology"},{"issue":"5","key":"10.1016\/j.pmn.2026.05.028_bib0028","first-page":"37","article-title":"Acute painful crises may be causes of sudden deaths in sickle cell diseases","volume":"21","author":"Helvaci","year":"2023","journal-title":"World Family Medicine"},{"issue":"8","key":"10.1016\/j.pmn.2026.05.028_bib0029","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jval.2021.02.014","article-title":"Indirect economic burden of sickle cell disease","volume":"24","author":"Holdford","year":"2021","journal-title":"Value in Health"},{"key":"10.1016\/j.pmn.2026.05.028_bib0030","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jval.2018.07.826","article-title":"The economic burden of sickle cell disease in the United States","volume":"21","author":"Huo","year":"2018","journal-title":"Value in Health"},{"issue":"3","key":"10.1016\/j.pmn.2026.05.028_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/adolescents5030030","article-title":"Determining predictors of academic performance in children and adolescents with sickle cell disease and comparing it with siblings in Benin","volume":"5","author":"Ikediashi","year":"2025","journal-title":"Adolescents"},{"issue":"4","key":"10.1016\/j.pmn.2026.05.028_bib0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.hermed.2013.05.003","article-title":"Biochemical assessment of Ciklavit, a nutraceutical used in sickle cell anaemia management","volume":"3","author":"Imaga","year":"2013","journal-title":"Journal of Herbal Medicine"},{"issue":"11","key":"10.1016\/j.pmn.2026.05.028_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276639","article-title":"Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria","volume":"17","author":"Isa","year":"2022","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0034","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12967-021-03074-z","article-title":"Vaso-occlusive crisis in sickle cell disease: A vicious cycle of secondary events","volume":"19","author":"Jang","year":"2021","journal-title":"Journal of Translational Medicine"},{"issue":"3","key":"10.1016\/j.pmn.2026.05.028_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","article-title":"Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0036","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1038\/s41598-024-57473-5","article-title":"Brain network hypersensitivity underlies pain crises in sickle cell disease","volume":"14","author":"Joo","year":"2024","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pmn.2026.05.028_bib0037","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.htct.2023.06.007","article-title":"Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease","volume":"46","author":"Karimi","year":"2024","journal-title":"Hematology, Transfusion and Cell Therapy"},{"issue":"9","key":"10.1016\/j.pmn.2026.05.028_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30440","article-title":"Barriers to medication adherence in sickle cell disease: A comprehensive theory-based evaluation using the COM-B model","volume":"70","author":"King","year":"2023","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/aam.aam_36_20","article-title":"Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers","volume":"20","author":"Korubo","year":"2021","journal-title":"Annals of African Medicine"},{"issue":"4","key":"10.1016\/j.pmn.2026.05.028_bib0040","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4103\/NJM.NJM_29_20","article-title":"Biopsychosocial complications of pentazocine dependence: A case report from a co-occurring treatment facility in Lagos","volume":"29","author":"Koyejo","year":"2020","journal-title":"Nigerian Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pmn.2026.05.028_bib0041","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/bloodadvances.2023010749","article-title":"Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease","volume":"8","author":"Krishnamurti","year":"2024","journal-title":"Blood Advances"},{"issue":"14","key":"10.1016\/j.pmn.2026.05.028_bib0042","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/bloodadvances.2023012477","article-title":"Costs and impact of disease in adults with sickle cell disease: A pilot study","volume":"8","author":"Lanzkron","year":"2024","journal-title":"Blood Advances"},{"key":"10.1016\/j.pmn.2026.05.028_bib0043","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJGM.S257340","article-title":"Patient-reported outcomes and economic burden of adults with sickle cell disease in the United States: A systematic review","volume":"13","author":"Lee","year":"2020","journal-title":"International Journal of General Medicine"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0044","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/jwas.jwas_90_23","article-title":"Tissue necrosis: A burden of pentazocine abuse in South East Nigeria","volume":"14","author":"Mba","year":"2024","journal-title":"Journal of the West African College of Surgeons"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0045","first-page":"37","article-title":"Fisiopatolog\u00eda cl\u00ednica en pacientes con enfermedad de c\u00e9lulas falciformes: la transici\u00f3n del dolor agudo al cr\u00f3nico [Clinical pathophysiology in patients with sickle cell disease: The transition from acute to chronic pain]","volume":"28","author":"Mugabure Bujedo","year":"2020","journal-title":"Revista Espa\u00f1ola del Dolor"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0046","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/s12913-024-11125-6","article-title":"Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, A qualitative study","volume":"24","author":"Namaganda","year":"2024","journal-title":"BMC Health Services Research"},{"key":"10.1016\/j.pmn.2026.05.028_bib0047","series-title":"African natural plant products: New discoveries and challenges in chemistry and quality","first-page":"263","article-title":"Nicosan: Phytomedicinal treatment for sickle cell disease","author":"Nathan","year":"2010"},{"key":"10.1016\/j.pmn.2026.05.028_bib0048","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3877882","article-title":"Pentazocine misuse among sickle cell disease patients and the role of lack of enforcement of opioid dispensing regulations by community pharmacies: A descriptive observational study","volume":"2022","author":"Nnachi","year":"2022","journal-title":"Advances in Public Health"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0049","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/NJM.NJM_1_20","article-title":"Analgesia self-medication practice and pentazocine dependency in adult sickle cell patients in Southeast Nigeria","volume":"29","author":"Nwagha","year":"2020","journal-title":"Nigerian Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pmn.2026.05.028_bib0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/tropej\/fmz070","article-title":"Effectiveness and safety of hydroxyurea in the treatment of sickle cell anaemia children in Jos, North Central Nigeria","volume":"66","author":"Ofakunrin","year":"2020","journal-title":"Journal of Tropical Pediatrics"},{"key":"10.1016\/j.pmn.2026.05.028_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.765958","article-title":"Barriers to therapeutic use of hydroxyurea for sickle cell disease in Nigeria: A cross-sectional survey","volume":"12","author":"Okocha","year":"2022","journal-title":"Frontiers in Genetics"},{"issue":"5","key":"10.1016\/j.pmn.2026.05.028_bib0052","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4103\/NJM.NJM_17_23","article-title":"Low uptake of hydroxyurea among a cohort of sickle cell disease patients in Nigeria","volume":"32","author":"Okoye","year":"2023","journal-title":"Nigerian Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pmn.2026.05.028_bib0053","first-page":"69","article-title":"Pain index and health-related quality of life in a Nigerian patient\u2019s cohort with sickle cell anaemia","volume":"20","author":"Olowoselu","year":"2021","journal-title":"African Journal of Medical and Health Sciences"},{"issue":"4","key":"10.1016\/j.pmn.2026.05.028_bib0054","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7196\/SAJCH.2015.v9i4.968","article-title":"Acute pain management in children with sickle cell anaemia during emergency admission to a teaching hospital in Lagos","volume":"9","author":"Oshikoya","year":"2015","journal-title":"Nigeria. South African Journal of Child Health"},{"issue":"4","key":"10.1016\/j.pmn.2026.05.028_bib0055","first-page":"404","article-title":"Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Sickle Cell World Assessment Survey (SWAY). American Journal of Hematology"},{"issue":"3","key":"10.1016\/j.pmn.2026.05.028_bib0056","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jha2.188","article-title":"Gabapentin for acute pain in sickle cell disease: A randomized double-blinded placebo-controlled phase II clinical trial","volume":"2","author":"Puri","year":"2021","journal-title":"EJHaem"},{"issue":"16","key":"10.1016\/j.pmn.2026.05.028_bib0057","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/bloodadvances.2023012467","article-title":"Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease","volume":"8","author":"Saraf","year":"2024","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0058","doi-asserted-by":"crossref","first-page":"52","DOI":"10.36469\/jheor.2020.12852","article-title":"Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: A retrospective claims study","volume":"7","author":"Shah","year":"2020","journal-title":"Journal of Health Economics and Outcomes Research"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/children8020084","article-title":"Neuropathic pain in children with sickle cell disease: The hidden side of the vaso-occlusive crisis","volume":"8","author":"Sigalla","year":"2021","journal-title":"Children"},{"issue":"6","key":"10.1016\/j.pmn.2026.05.028_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/AJP.0000000000000289","article-title":"Psychosocial and functional outcomes in youth with chronic sickle cell pain","volume":"32","author":"Sil","year":"2016","journal-title":"The Clinical Journal of Pain"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0061","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0062","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2049463720920682","article-title":"Mechanisms of pain in sickle cell disease","volume":"15","author":"Takaoka","year":"2021","journal-title":"British Journal of Pain"},{"issue":"2","key":"10.1016\/j.pmn.2026.05.028_bib0063","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.pmn.2026.05.028_bib0064","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1182\/bloodadvances.2023011477","article-title":"One-year safety and efficacy of mitapivat in sickle cell disease: Follow-up results of a phase 2, open-label study","volume":"7","author":"van Dijk","year":"2023","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pmn.2026.05.028_bib0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0027-9684(15)30471-5","article-title":"Patient-reported outcomes: Descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease","volume":"102","author":"Wilkie","year":"2010","journal-title":"Journal of the National Medical Association"}],"container-title":["Pain Management Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904226002018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904226002018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:09:18Z","timestamp":1782187758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1524904226002018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":64,"alternative-id":["S1524904226002018"],"URL":"https:\/\/doi.org\/10.1016\/j.pmn.2026.05.028","relation":{},"ISSN":["1524-9042"],"issn-type":[{"value":"1524-9042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SCD Medications Use and Pain Events Among SCD Patients in a Nigerian Hospital","name":"articletitle","label":"Article Title"},{"value":"Pain Management Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmn.2026.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}